Core Insights - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with a lead program for deramiocel aimed at treating Duchenne muscular dystrophy (DMD) [1][3] - The company will present updates on its progress and scientific developments at various upcoming investor and scientific conferences [2] Company Overview - Capricor Therapeutics, Inc. (NASDAQ: CAPR) is dedicated to advancing innovative therapies for rare diseases, with deramiocel (CAP-1002) being a key product candidate currently in Phase 3 clinical development for DMD [3] - Deramiocel is an allogeneic cardiac-derived cell therapy that has shown immunomodulatory, antifibrotic, and regenerative properties in preclinical and clinical studies [3] - The company is also developing its proprietary StealthX™ platform for exosome technology, targeting applications in vaccinology and the delivery of therapeutics [3] Commercial Agreements - Capricor has entered into an exclusive agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of deramiocel in the United States and Japan, pending regulatory approval [5]

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Linda Marban – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Joseph Pantginis – H.C. Wainwright Leland Gershell – Oppenheimer Aydin Huseynov – Ladenburg Rick Miller – Cantor Operator Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2024 Earnings Call. At this time, all participant lines are in a lis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or ot ...

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.38%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.11 per share when it actually produced a loss of $0.31, delivering a surprise of -181.82%. Over the last four quarters, ...

Exhibit 99.1 Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update -Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at ...

-Company to Host Conference Call, August 7, 2024 at 4:30 p.m. ET- Conference Call Details: SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the second quarter ended June 30, 2024, after the market close on Wednesday, August 7, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7. ...

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by sign ...

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Pre-BLA Meeting with FDA Scheduled for Q3 2024 to Discuss Options to Expedite BLA Filing- SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional positive 3-year safety and efficacy results from its ongoing ...

About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically ta ...

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP1002), for the treatment of Duchenne Muscular Dystrophy (DMD). Capricor's goal for this meeting will be to finali ...